Assessing the role of drugs in suicidal ideation and suicidality.
The emergence of suicidal ideation and suicide-related behaviour in patients receiving drug treatment is of concern because of the overall burden of these conditions and the possible link with completed suicide. Observational studies have been useful in generating hypotheses of causality but are confounded by the association between various disease states and increased suicide-related behaviour and completed suicide. The demonstration of causality requires experimental studies, especially randomised controlled trials, and meta-analyses. Unfortunately, the lack of uniform requirements for defining, detecting and recording suicidal ideation, suicide-related behaviour and completed suicide creates difficulties in comparing studies. Nevertheless, there is evidence of an association between SSRIs and other newer antidepressant drugs and treatment-emergent suicidal ideation and suicide-related behaviour in both children and adults; however, an increase in completed suicide as a result of treatment with SSRIs and other newer antidepressant drugs has not been demonstrated. Atomoxetine has also been associated with treatment-emergent suicidality, based on the results of a meta-analysis. Although similar associations have been proposed for some antiepileptic drugs, isotretinoin and interferon-alpha, they are yet to be supported by evidence from randomised controlled trials or meta-analyses.
Reith
David M
DM
Dunedin School of Medicine, University of Otago, Dunedin, New Zealand. david.reith@stonebow.otago.ac.nz
Edmonds
Liza
L
D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D003866:Depressive Disorder / Q000188:drug therapy; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D001523:Mental Disorders / Q000139:chemically induced* / Q000517:prevention & control / Q000523:psychology; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D013405:Suicide / Q000523:psychology* / Q000706:statistics & numerical data; D000092864:Suicide Prevention
D000928:Antidepressive Agents; D004364:Pharmaceutical Preparations; D017367:Selective Serotonin Reuptake Inhibitors